Previous Article | Next Article 
Journal of Clinical Microbiology, December 2008, p. 4056-4057, Vol. 46, No. 12
0095-1137/08/$08.00+0 doi:10.1128/JCM.01372-08
Copyright © 2008, American Society for Microbiology. All Rights Reserved.
Long-Term Follow-Up of Methicillin-Resistant Staphylococcus aureus Molecular Epidemiology after Emergence of Clone USA300 in San Francisco Jail Populations
Pierre Tattevin,
Binh An Diep,
Michael Jula, and
Françoise Perdreau-Remington*
Department of Medicine, Division of Infectious Diseases, San Francisco General Hospital, University of California, San Francisco, California
Received 17 July 2008/
Returned for modification 25 September 2008/
Accepted 7 October 2008

ABSTRACT
We performed a longitudinal analysis of 502 unique methicillin-resistant
Staphylococcus aureus (MRSA) clinical isolates originating from
San Francisco jail inmates between 2000 and 2007. Strain USA300,
first encountered in 2001, accounted for 82.1% (412/502) of
MRSA infections. Non-USA300 MRSA strains were rarely found after
2005 (one isolate in 2006, three in 2007).

TEXT
Since 2001, a dramatic increase in the number of methicillin-resistant
Staphylococcus aureus (MRSA) infections has been observed in
the United States, mostly related to the emergence of the USA300
clone in the community (
3,
6) and, subsequently, in hospitals
(
21). Correctional facility inmates were among the first communities
in which outbreaks of MRSA USA300 were reported in Mississippi
(
5), Georgia (
4), Texas (
2), California (
19), New York (
15),
and Canada (
1,
16). Thus far, no long-term data are available
to describe the evolution of MRSA epidemiology since USA300
was introduced into these institutions. USA300 was first encountered
in San Francisco in 2001 (
3). We performed a longitudinal analysis
of all clinical MRSA isolates originating from San Francisco
jail inmates during the years 2000 to 2007.
The San Francisco County jail system houses an average daily population of 2,200 inmates in five jails (20). A retrospective review was conducted of the electronic records for all cultures positive for S. aureus that were performed in the San Francisco General Hospital Clinical Microbiology Laboratory, which receives specimens from the Jail Health Services. Aside from the specimen source, collection date, sex, and age, no clinical information was accessible. Data collection was approved by the Committee on Human Research, Office of Research Administration, at the University of California, San Francisco, CA. Isolates were tested for oxacillin resistance by the salt agar method, and the presence of the mecA gene was confirmed by PCR. Susceptibility to other antimicrobial agents was tested using broth microdilution with the MicroScan WalkAway 96 instrument (Dade Behring), and the results were interpreted in accordance with NCCLS guidelines (M7-A5). Samples obtained for colonization screening were excluded. Only one isolate per patient per year was studied. MRSA isolates were genotyped by pulsed-field gel electrophoresis following SmaI macrorestriction digest of chromosomal DNA (23), spa typing (22), and multilocus sequence typing (8). USA300 was further defined by the presence of Panton-Valentine leukocidin genes (lukF-PV and lukS-PV) and the arginine catabolic mobile element by using PCR assays. The SCCmec type was identified using a PCR-based protocol (18). Chi-square tests were used for bivariate analysis, and chi-square tests for trends were used to evaluate secular trends. All statistical calculations were carried out using Stata version 9.1 (College Station, TX).
Between 2000 and 2007, 656 cultures positive for S. aureus were recorded. Of these, 510 (77.7%) were MRSA. Eight MRSA isolates were excluded, because they were obtained by colonization screening (n = 7) or were not available for typing (n = 1). Thus, 502 MRSA isolates were analyzed, originating from 494 patients, with a median age of 39 years (interquartile range, 32 to 47) and a male-to-female ratio of 3.9. There was a significant increase in the incidence of MRSA infections over time (P = 0.01), from 25 in 2000 to 60 in 2007, while the incidence of methicillin-susceptible S. aureus (MSSA) infections remained stable at
20 isolates per year. Of the 502 MRSA isolates analyzed, 412 (82.1%) were USA300 (ST8, SCCmec type IVa), 34 (6.8%) were USA1100 (ST30, SCCmec type IVa), 27 (5.4%) were USA500 (ST8, SCCmec type IVa), 16 (3.2%) were USA1000 (ST59, SCCmec type IVa), and 3 were USA100 (ST5, SCCmec type II). USA300 appeared in 2001, accounting for 8 of 22 MRSA isolates (36.4%) that year. Its incidence peaked at 128/140 isolates (91.4%) in 2004 and stabilized at 45 to 60 per year from 2005 to 2007, suggesting that USA300 has become endemic in San Francisco jails (Fig. 1). Non-USA300 MRSA isolates were rarely found after 2005 (1 of 47 isolates in 2006, 3 of 60 in 2007). MRSA was mostly isolated from skin or skin structure infections (SSSI) throughout the study period (mean rate, 92.9% of all specimens). No significant changes in antimicrobial resistance were observed over time for MRSA, with a mean resistance rate at 46.8% for ciprofloxacin, 15.7% for tetracycline, 9.3% for clindamycin, 0.7% for trimethoprim-sulfamethoxazole, and 0.0% for vancomycin and linezolid.
Although previous reports have described community-associated
MRSA (CA-MRSA) outbreaks in jails (
4,
5,
16), performed colonization
surveillance cultures (
16,
25), or studied risk factors for
MRSA in these settings (
1,
2,
24,
25), they focused on limited
periods of time. This study shows that, 5 years after its emergence
in San Francisco jails, USA300 has replaced virtually all previously
encountered CA-MRSA clones. As previously reported (
14,
17),
USA300 was primarily associated with SSSI in this study and
was usually susceptible to trimethoprim-sulfamethoxazole, clindamycin,
and tetracycline (
3), with no significant increase in antimicrobial
resistance over time, as opposed to recent reports from other
settings (
7,
10). Large jails have been identified as likely
foci for the amplification and subsequent spread of MRSA in
the surrounding communities (
12,
13), and it was predicted that
public health interventions directed at these "superspreader
institutions" could have a disproportionate impact on controlling
CA-MRSA epidemics (
11). Our study adds another incentive for
improving infection control in these institutions by showing
the persistently high incidence of MRSA infections once USA300
is introduced, in the absence of dedicated intervention. Guidelines
aiming at reducing CA-MRSA transmission in communities are available
(
9), and significant reductions in MRSA transmission have been
achieved in correctional facilities, through a comprehensive
intervention program, in Georgia (
24).
This study was limited by its reliance on retrospective data collection and the absence of active surveillance cultures. However, as the incidence of positive cultures for MSSA remained stable, it is unlikely that profound changes in sampling policies occurred during the study period. Only documented MRSA infections could be analyzed, although most patients presenting with SSSI in such facilities are treated without microbiological sampling (15). Thus, these figures likely represent an important underestimation of the true incidence of MRSA infections. Despite these limitations, this study shows that USA300, 5 years after its introduction into San Francisco jails, has virtually replaced all previous MRSA clones and is associated with a two- to three-times-higher incidence of MRSA infections than the pre-USA300 era.

ACKNOWLEDGMENTS
This work was supported by an unrestricted grant from Pfizer
to F.P.-R. P.T. was supported by a grant from the Société
de Pathologie Infectieuse de Langue Française (SPILF)
and by the Pontchaillou University Hospital, Rennes, France.
B.A.D. was supported by a Microbial Pathogenesis and Host Defense
Postdoctoral Fellowship (5T32AI060537-02) from the University
of California, San Francisco, CA.

FOOTNOTES
* Corresponding author. Mailing address: Department of Medicine, Division of Infectious Diseases, San Francisco General Hospital, 1001 Potrero Avenue, San Francisco, CA 94143-0811. Phone: (415) 206-8666. Fax: (415) 648-8425. E-mail:
fpr{at}epi-center.ucsf.edu 
Published ahead of print on 15 October 2008. 

REFERENCES
1 - Aiello, A. E., F. D. Lowy, L. N. Wright, and E. L. Larson. 2006. Methicillin-resistant Staphylococcus aureus among US prisoners and military personnel: review and recommendations for future studies. Lancet Infect. Dis. 6:335-341.[CrossRef][Medline]
2 - Baillargeon, J., M. F. Kelley, C. T. Leach, G. Baillargeon, and B. H. Pollock. 2004. Methicillin-resistant Staphylococcus aureus infection in the Texas prison system. Clin. Infect. Dis. 38:e92-e95.[CrossRef][Medline]
3 - Carleton, H. A., B. A. Diep, E. D. Charlebois, G. F. Sensabaugh, and F. Perdreau-Remington. 2004. Community-adapted methicillin-resistant Staphylococcus aureus (MRSA): population dynamics of an expanding community reservoir of MRSA. J. Infect. Dis. 190:1730-1738.[CrossRef][Medline]
4 - Centers for Disease Control and Prevention. 2003. Methicillin-resistant Staphylococcus aureus infections in correctional facilities—Georgia, California, and Texas, 2001-2003. MMWR Morb. Mortal. Wkly. Rep. 52:992-996.[Medline]
5 - Centers for Disease Control and Prevention. 2001. Methicillin-resistant Staphylococcus aureus skin or soft tissue infections in a state prison—Mississippi, 2000. MMWR Morb. Mortal. Wkly. Rep. 50:919-922.[Medline]
6 - Chambers, H. F. 2001. The changing epidemiology of Staphylococcus aureus? Emerg. Infect. Dis. 7:178-182.[Medline]
7 - Diep, B. A., H. F. Chambers, C. J. Graber, J. D. Szumowski, L. G. Miller, L. L. Han, J. H. Chen, F. Lin, J. Lin, T. Haivan Phan, H. A. Carleton, L. K. McDougal, F. C. Tenover, D. E. Cohen, K. H. Mayer, G. F. Sensabaugh, and F. Perdreau-Remington. 2008. Emergence of multidrug-resistant, community-associated, methicillin-resistant Staphylococcus aureus clone USA300 in men who have sex with men. Ann. Intern. Med. 148:249-257.[Abstract/Free Full Text]
8 - Enright, M. C., N. P. Day, C. E. Davies, S. J. Peacock, and B. G. Spratt. 2000. Multilocus sequence typing for characterization of methicillin-resistant and methicillin-susceptible clones of Staphylococcus aureus. J. Clin. Microbiol. 38:1008-1015.[Abstract/Free Full Text]
9 - Gorwitz, R. J., D. B. Jernigan, J. H. Powers, J. A. Jernigan, et al. 2006. Strategies for clinical management of MRSA in the community: summary of an experts' meeting convened by the Centers for Disease Control and Prevention. http://www.cdc.gov/ncidod/dhqp/ar_mrsa_ca.html.
10 - Han, L. L., L. K. McDougal, R. J. Gorwitz, K. H. Mayer, J. B. Patel, J. M. Sennott, and J. L. Fontana. 2007. High frequencies of clindamycin and tetracycline resistance in methicillin-resistant Staphylococcus aureus pulsed-field type USA300 isolates collected at a Boston ambulatory health center. J. Clin. Microbiol. 45:1350-1352.[Abstract/Free Full Text]
11 - Hartley, D. M., J. P. Furuno, M. O. Wright, D. L. Smith, and E. N. Perencevich. 2006. The role of institutional epidemiologic weight in guiding infection surveillance and control in community and hospital populations. Infect. Control Hosp. Epidemiol. 27:170-174.[CrossRef][Medline]
12 - Hota, B., C. Ellenbogen, M. K. Hayden, A. Aroutcheva, T. W. Rice, and R. A. Weinstein. 2007. Community-associated methicillin-resistant Staphylococcus aureus skin and soft tissue infections at a public hospital: do public housing and incarceration amplify transmission? Arch. Intern. Med. 167:1026-1033.[Abstract/Free Full Text]
13 - Kajita, E., J. T. Okano, E. N. Bodine, S. P. Layne, and S. Blower. 2007. Modeling an outbreak of an emerging pathogen. Nat. Rev. Microbiol. 5:700-709.[CrossRef][Medline]
14 - King, M. D., B. J. Humphrey, Y. F. Wang, E. V. Kourbatova, S. M. Ray, and H. M. Blumberg. 2006. Emergence of community-acquired methicillin-resistant Staphylococcus aureus USA 300 clone as the predominant cause of skin and soft-tissue infections. Ann. Intern. Med. 144:309-317.[Abstract/Free Full Text]
15 - Lowy, F. D., A. E. Aiello, M. Bhat, V. D. Johnson-Lawrence, M. H. Lee, E. Burrell, L. N. Wright, G. Vasquez, and E. L. Larson. 2007. Staphylococcus aureus colonization and infection in New York state prisons. J. Infect. Dis. 196:911-918.[CrossRef][Medline]
16 - Main, C. L., P. Jayaratne, A. Haley, C. Rutherford, F. Smaill, and D. N. Fisman. 2005. Outbreaks of infection caused by community-acquired methicillin-resistant Staphylococcus aureus in a Canadian correctional facility. Can. J. Infect. Dis. Med. Microbiol. 16:343-348.[Medline]
17 - Moran, G. J., R. N. Amii, F. M. Abrahamian, and D. A. Talan. 2005. Methicillin-resistant Staphylococcus aureus in community-acquired skin infections. Emerg. Infect. Dis. 11:928-930.[Medline]
18 - Oliveira, D. C., and H. de Lencastre. 2002. Multiplex PCR strategy for rapid identification of structural types and variants of the mec element in methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 46:2155-2161.[Abstract/Free Full Text]
19 - Pan, E. S., B. A. Diep, H. A. Carleton, E. D. Charlebois, G. F. Sensabaugh, B. L. Haller, and F. Perdreau-Remington. 2003. Increasing prevalence of methicillin-resistant Staphylococcus aureus infection in California jails. Clin. Infect. Dis. 37:1384-1388.[CrossRef][Medline]
20 - San Francisco Government. 2006. San Francisco jails: an investigative visit. A report of the 2005-2006 civil grand jury for the city and county of San Francisco. http://www.sfgov.org/site/uploadedfiles/courts/SFJails_2006.pdf.
21 - Seybold, U., E. V. Kourbatova, J. G. Johnson, S. J. Halvosa, Y. F. Wang, M. D. King, S. M. Ray, and H. M. Blumberg. 2006. Emergence of community-associated methicillin-resistant Staphylococcus aureus USA300 genotype as a major cause of health care-associated blood stream infections. Clin. Infect. Dis. 42:647-656.[CrossRef][Medline]
22 - Shopsin, B., M. Gomez, S. O. Montgomery, D. H. Smith, M. Waddington, D. E. Dodge, D. A. Bost, M. Riehman, S. Naidich, and B. N. Kreiswirth. 1999. Evaluation of protein A gene polymorphic region DNA sequencing for typing of Staphylococcus aureus strains. J. Clin. Microbiol. 37:3556-3563.[Abstract/Free Full Text]
23 - Tenover, F. C., L. K. McDougal, R. V. Goering, G. Killgore, S. J. Projan, J. B. Patel, and P. M. Dunman. 2006. Characterization of a strain of community-associated methicillin-resistant Staphylococcus aureus widely disseminated in the United States. J. Clin. Microbiol. 44:108-118.[Abstract/Free Full Text]
24 - Wootton, S. H., K. Arnold, H. A. Hill, S. McAllister, M. Ray, M. Kellum, M. LaMarre, M. E. Lane, J. Chaitram, S. Lance-Parker, and M. J. Kuehnert. 2004. Intervention to reduce the incidence of methicillin-resistant Staphylococcus aureus skin infections in a correctional facility in Georgia. Infect. Control Hosp. Epidemiol. 25:402-407.[CrossRef][Medline]
25 - Wright, M. O., J. P. Furuno, R. A. Venezia, J. K. Johnson, H. C. Standiford, J. N. Hebden, J. Hill, D. M. Hartley, A. D. Harris, and E. N. Perencevich. 2007. Methicillin-resistant Staphylococcus aureus infection and colonization among hospitalized prisoners. Infect. Control Hosp. Epidemiol. 28:877-879.[CrossRef][Medline]
Journal of Clinical Microbiology, December 2008, p. 4056-4057, Vol. 46, No. 12
0095-1137/08/$08.00+0 doi:10.1128/JCM.01372-08
Copyright © 2008, American Society for Microbiology. All Rights Reserved.